Which of the following is accurate regarding semaglutide’s new indication to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD)? A. The American Diabetes Association guidelines purposefully do not recognize this data B. This indication is based on clinical study data versus metformin C. This indication is specific to patients with significantly uncontrolled diabetes D. Semaglutide is the first GLP-1 agonist to have received this indication
[Expert Solution]: Which of the following is accurate…
Need help with your Endocrine & Metabolic Disorders case study or NCLEX preparation? Connect with a verified Nursing expert now.